PremiumThe FlyReplimune files $250M mixed securities shelf Replimune Group files to sell 25.1M shares of common stock for holders Replimune Group Advances Oncolytic Immunotherapy Pipeline PremiumThe FlyReplimune price target raised to $18 from $16 at JPMorgan Replimune Group’s Promising Milestones and Strong Financial Position Drive Buy Rating Replimune price target raised to $22 from $21 at H.C. Wainwright PremiumPre-EarningsReplimune Group (REPL) Q3 Earnings Cheat Sheet Biotech Alert: Searches spiking for these stocks today Replimune price target raised to $27 from $18 at BMO Capital 
